CB-5083 order Significant clinical factors associated with LVH were systolic BP (OR 1.23; 95 % CI 1.134–1.323; P < 0.001), diastolic BP (OR 1.16; 95 % CI 1.031–1.306; P = 0.014), pulse pressure (OR 1.25; 95 % CI 1.137–1.380; P < 0.001), eGFR (OR 0.98; 95 % CI 0.968–0.9991; P = 0.0004; Fig. 2a, b), BMI (OR 1.15; 95 % CI 1.110–1.199; P < 0.0001; Fig. 3a, b), serum uric acid (OR 1.10; 95 % CI 1.002–1.202; www.selleckchem.com/products/Lapatinib-Ditosylate.html P = 0.046), ACR (OR 1.55; 95 % CI 1.267–1.905; P < 0.001),
A1C (OR 1.17; 95 % CI 1.011–1.345; P = 0.035), serum levels of iPTH (OR 1.00; 95 % CI 1.001–1.005; P < 0.001), HDL cholesterol (OR 0.98; 95 % CI 0.971–0.989; P < 0.001), triglyceride (OR 1.00; 95 % CI 1.001–1.003; P < 0.001), calcium (OR 0.56; 95 % CI 0.431–0.720; P < 0.001) and phosphorus (OR 1.23; 95 % CI 1.004–1.515; P = 0.046), and prescription of antihypertensive agents (OR 3.51; 95 % CI 1.601–7.685; P = 0.002). Table 5 Factors associated with LVMI (univariate logistic regression analysis) Variables OR 95 % CI P value Sex (female) 1.78 1.308–2.416 <0.001 Age (years) 1.00 0.990–1.015 0.690 Smoking 0.69 0.444–1.064 0.092 Menopause 1.269 0.858–1.877 0.233 Complications Diabetes 1.66 1.254–2.186 <0.001 Dyslipidemia
1.43 1.007–2.040 0.045 Hypertension 3.73 1.487–9.376 0.005 Medical history Hypertension 0.91 0.648–1.281 HKI-272 solubility dmso 0.592 Cardiovascular disease 0.72 0.518–1.013 0.060 MI 0.79 0.395–1.599 0.519 Angina 0.70 0.419–1.170 0.174 Congestive heart failure 0.40 0.142–1.146 0.088 ASO 1.21 0.562–2.609 0.625 Stroke 0.78 0.478–1.257 0.302 Blood pressure (mmHg) Systolic 1.23 1.134–1.323 <0.001 Diastolic 1.16 1.031–1.306
0.014 Pulse pressure (mmHg) 1.25 1.137–1.380 <0.001 BMI (kg/m2) 1.15 1.110–1.199 <0.001 eGFR (ml/min/1.73 m2) 0.98 0.968–0.991 <0.001 Uric acid (mg/dl) 1.10 1.002–1.202 0.046 Urinary albumin (mg/gCr) 1.55 1.267–1.905 <0.001 A1C (%) 1.17 1.011–1.345 0.035 Hemoglobin (g/dl) 0.98 0.905–1.052 0.520 iPTH (pg/ml) 1.00 1.001–1.005 <0.001 Total chol (mg/dl) 1.00 0.994–1.001 0.163 Non-HDL chol (mg/dl) 1.00 0.997–1.004 0.743 LDL chol (mg/dl) 1.00 0.997–1.006 0.545 HDL chol (mg/dl) 0.98 0.971–0.989 <0.001 Triglyceride (mg/dl) 1.00 1.001–1.003 <0.001 Calcium (mg/dl) 0.56 0.431–0.720 <0.001 Phosphorus (mg/dl) 1.23 1.004–1.515 0.046 Medication Antihypertensive agent 3.51 1.601–7.685 0.002 Statin 0.82 0.607–1.098 0.179 ESA 1.12 0.726–1.732 0.605 Phosphate Meloxicam binder 1.06 0.476–2.348 0.892 Vitamin D 0.80 0.438–1.444 0.452 OR odds ratio, CI confidence interval, ESA erythropoiesis-stimulating agent Fig. 2 Relationship between estimated glomerular filtration rate (eGFR) and left ventricular mass index (LVMI) of patients with stage 3–5 CKD. a female; b male Fig. 3 Relationship between body mass index (BMI) and left ventricular mass index (LVMI) of patients with stage 3–5 CKD. a Female; b male As shown in Table 6, the variables independently associated with LVH were past history of CVD (OR 0.574; 95 % CI 0.360–0.916; P = 0.